Familymeds 8-K Regulation FD Disclosure

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 21, 2006

DrugMax, Inc.

(Exact name of registrant as specified in its charter)

STATE OF NEVADA	1-15445	34-1755390
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

312 Farmington Avenue

Farmington, CT 06032-1968

(Address of principal executive offices)

Registrant’s telephone number, including area code: (860) 676-1222

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c)) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01  Regulation FD Disclosure.

As previously disclosed, on February 21, 2006, DrugMax, Inc. Chairman & Chief Executive Officer, Edgardo A. Mercadante, provided a presentation at the Roth Capital Partners 18th Annual Growth Stock Conference, held at the St. Regis Monarch Beach Resort & Spa in Dana Point, CA, which presentation was web cast simultaneously through a link provided at DrugMax’s web site (www.drugmax.com). A transcript of the presentation and the slides used during the presentation are archived at www.drugmax.com and will be available for viewing and listening for the next 90 days. Copies also are attached hereto as Exhibits 99.1 and 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into filings under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01  Financial Statements and Exhibits.

99.1 Transcript of February 21, 2006 Web Cast

99.2 Slideshow Presentation

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

DRUGMAX, INC.
By:	/s/ Edgardo A. Mercadante
	Edgardo A. Mercadante, Chief Executive Officer,  President and Chairman of the Board

Dated:February 22, 2006

3

EXHIBIT INDEX

Exhibit

NumberExhibit Description

99.1    Transcript of February 21, 2006 Web Cast

99.2    Slideshow Presentation

4